Señales en vivo de VSTM | Maximiza tus Ganancias con Getagraph.com

COMPRAR 111208 min ago

@ $11.85

Emitido: 14 feb 2024 @ 13:14

Retorno: -15.78%

Señal anterior: feb 13 - 12:38

Señal anterior: Vender

Retorno: 1.28 %

Live Chart Being Loaded With Signals

Commentary (1 may 2024 @ 16:00):

Stats
Volumen de hoy	91 012.00
Volumen promedio	140 463
Capitalización de mercado	252.45M
EPS	$0 ( 2024-03-12 )
Próxima fecha de ganancias	( $-1.160 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.52
ATR14	$0.0380 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Calkins Daniel	Sell	6	Common Stock
2024-03-25	Calkins Daniel	Sell	25	Common Stock
2024-03-20	Calkins Daniel	Sell	55	Common Stock
2024-03-18	Gagnon Robert E.	Sell	283	Common Stock
2024-03-19	Gagnon Robert E.	Sell	130	Common Stock

INSIDER POWER
50.13
Last 99 transactions
Buy: 1 037 036 \| Sell: 241 539

Volumen Correlación

Largo: -0.18 (neutral)

Corto: 0.46 (neutral)

Signal:(51.073) Neutral

Verastem Inc Correlación

10 Correlaciones Más Positivas
PXLW	0.908
CVCY	0.885
IMAB	0.884
SRRK	0.882
ADXN	0.88
SHYF	0.875
FOXA	0.872
VIRC	0.863
CRTO	0.863
FLUX	0.86

10 Correlaciones Más Negativas
GRPH	-0.803
IKNX	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Verastem Inc Correlación - Moneda/Commodity

-0.65
( weak negative )

-0.36
( neutral )

0.18
( neutral )

-0.65
( weak negative )

0.74
( moderate )

Verastem Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-62 000.00 (0.00 %)
EPS:	$-3.96

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-62 000.00 (0.00 %)
EPS:	$-3.96

FY	2022
Ingresos:	$2.60M
Beneficio Bruto:	$2.48M (95.45 %)
EPS:	$-4.58

FY	2021
Ingresos:	$2.05M
Beneficio Bruto:	$2.05M (100.00 %)
EPS:	$-0.464

Financial Reports:

No articles found.

Verastem Inc

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.